Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
In a real-world population of adults with migraine, we would like to investigate whether 50
mg diclofenac potassium is non-inferior to 75 mg rimegepant in terms of pain freedom at 2
hours after drug intake.